Compare GV & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GV | SCNX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Other Pharmaceuticals |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 24.8M |
| IPO Year | 2022 | 2020 |
| Metric | GV | SCNX |
|---|---|---|
| Price | $1.35 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 65.5K | ★ 1.7M |
| Earning Date | 01-02-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,773,905.00 | $653,391.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 207.88 |
| 52 Week Low | $1.02 | $0.46 |
| 52 Week High | $9.60 | $8.19 |
| Indicator | GV | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | 42.76 |
| Support Level | $1.05 | $0.49 |
| Resistance Level | $1.48 | $0.60 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 51.92 | 15.46 |
Visionary Holdings Inc is a private education providing company located in Canada, with subsidiaries in Canada and market partners in China, that offers high-quality education resources to students around the globe. The company aims to provide access to secondary, college, undergraduate and graduate, and vocational education to students in Canada through technological innovation so that more people can learn, grow, and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the company has been serving and will continue to serve both Canadian and international students.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.